The latest from my team in Nature Medicine. We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me A 🧵 www.nature.com/articles/s41... - ThreadSky

zalaly.bsky.social • 37 days ago

The latest from my team in Nature Medicine.

We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound).

By @Biostayan, Taeyoung Choi and me

A 🧵
https://www.nature.com/articles/s41591-024-03412-w

Comments

dredecopp.bsky.social•37 days ago

My wife was on it briefly a few years back, now she's scheduled for surgery to remove her swollen thyroid. Found this the other day:
https://pubmed.ncbi.nlm.nih.gov/37656509/

levin.bsky.social•28 days ago

Can’t access. I’m wondering if it looks at the issues for pwLC. GLP has positive effects for some issues caused by LC but exercise is counterindicated for most pwLC due to PEM. Would GLP solve enough of the probs of LC to allow folks to workout? Or is the muscle loss slow enough to not be a problem?

fpaiano.bsky.social•37 days ago

📌

friend4thelonghaul.bsky.social•37 days ago

Thank you for this. I’m a long hauler since April 2020 and I just started a glp1 to assist a lot of my post-Rona induced issues, including metabolic syndrome after not eating for a year because of #mcas. I’m shocked by the impacts of my first week.

paarthotnax.bsky.social•32 days ago

What have the impacts been??

friend4thelonghaul.bsky.social•31 days ago

I wrote about the first week on my Substack here: https://open.substack.com/pub/f4lh/p/a-glp-fun-adventure?r=1pih9j&utm_medium=ios - I am sick right now but I’ll be updating about week 2 soon.

prez-omama.bsky.social•37 days ago

📌

joyfulkilljoy.bsky.social•37 days ago

📌

lifenotes2.bsky.social•37 days ago

📌

karendshipp.bsky.social•37 days ago

📌

geoffthornton.bsky.social•37 days ago

📌

h2obio.bsky.social•37 days ago

📌

annapsysoz.bsky.social•37 days ago

📌

njbbari3.bsky.social•37 days ago

📌

ambernoel.bsky.social•37 days ago

📌

zalaly.bsky.social•37 days ago

Why we did this study?

We saw that GLP1 use has substantially increased, and reports started to emerge about off-target beneficial effects. But realized that no one had comprehensively investigated effectiveness and risks of GLP-1 across all possible health outcomes

https://www.nature.com/articles/s41591-024-03412-w

zalaly.bsky.social•37 days ago

So, we decided to do the comprehensive study!

We did a discovery analysis which comprehensively examined 175 possible health outcomes (leaving no stone unturned) in 215,970 people on GLP1 and more than 2 million individuals not on GLP1.

https://www.nature.com/articles/s41591-024-03412-w

zalaly.bsky.social•37 days ago

We included several controls - people on sulfonylureas, DPP4 inhibitors, SGLT2 inhibitors and people on usual care who did not start GLP1
We followed study participants for 3.7 years
https://www.nature.com/articles/s41591-024-03412-w

zalaly.bsky.social•37 days ago

The results show that GLP1 have a wide-ranging beneficial profile but are not without risks.

GLP1 meds were associated with reduced risk of 42 (24%) outcomes and increased risk of 19 outcomes (11%).

https://www.nature.com/articles/s41591-024-03412-w

lakeginger.bsky.social•34 days ago

Did you examine the frequency of reduced risk versus increased risk?

zalaly.bsky.social•37 days ago

GLP1 reduced risks of substance use and psychotic disorders,
seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious
illnesses and several respiratory conditions.

zalaly.bsky.social•37 days ago

GLP1 increased risks of gastrointestinal disorders, hypotension, syncope, arthritic disorders,
nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.